Abstract. Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro. However, there are no reports that Tan-IIA is capable of inhibiting J5 HCC cell growth in vivo. In this study, J5 cells were implanted directly into nude SCID mice which were divided randomly into four groups to be treated with vehicle, Tan-IIA (30 mg/ kg of body weight, Q.week days 3 and 5), 5-FU (30 mg/ kg of body weight, Q.week day 1) or Tan-IIA (30 mg/ kg of body weight, Q.week days 3 and 5) plus 5-FU (30 mg/ kg of body weight, Q.week day 1). Each agent was injected intraperitoneally, with treatment starting 4 weeks after inoculation with J5 cells. Treatment with Tan-IIA 30 mg/ kg or with 30 mg/ kg of 5-FU resulted in a reduction in tumor size and weight compared with the control group. The protein expression of Bax and caspase-3 in the J5 xenograft tumors treated with Tan-IIA 30 mg/ kg or with 30 mg/kg of 5-FU was upregulated, whereas that of CD31 was downregulated compared with the control group. These findings indicate that Tan-IIA may inhibit tumor growth in a J5 xenograft animal model by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
Introduction
Hepatocellular carcinoma is the leading cause of cancer-related death in men (41.4/ 100,000 deaths) in Taiwan (1) . HCC is chemoresistant to a number of available chemotherapeutic agents (2) . Numerous prescription drugs in use for cancer treatment are derived from plants (3) . Tanshinone IIA (Tan-IIA) is an extract from Salviae Miltiorrhizae radix (4, 5) , and its antiinflammatory activities (6, 7) , antitumor activity in numerous human cancer cell types (8) (9) (10) and anti-oxidant properties (11, 12) have been well documented. In addition, it has been extensively reported that Tan-II A inhibits cell proliferation and induces apoptosis in hepatocellular carcinoma cell lines (13) (14) (15) . Tan-IIA effectively inhibited the invasion and metastasis of HCC cells in vitro and in vivo (16) . Our previous study revealed that Tan-IIA inhibited hep-J5 cell growth in vitro via induction of apoptosis and increase in protein expression of calreticulin, caspase 12 and GADD153 (17) . However, the anticancer effects of Tan-IIA on hep-J5 cells in vivo are not yet fully understood. The present study focused on the anticancer effect of Tan-IIA in vivo in SCID mice, using a human hepatocellular carcinoma xenograft model of J5 cells. Additionally, since 5-fluorouracil (5-FU) is one of the chemotherapeutic agents for HCC, we also examined whether there were any synergistic effects between Tan-IIA and 5-FU in this study. The J5 cells were maintained in RPMI-1640 medium containing 10% FBS, 1% penicillin-streptomycin (10,000 U/ ml penicillin; 10 mg/ ml streptomycin) in a 37˚C humidified atmosphere containing 5% CO 2 .
Materials and methods

Chemicals
In vivo J5 cell tumor xenograft model. 6 /0.2 ml) and maintained in a pathogen-free environment (Laboratory Animal Center of Tzu Chi University, Hualien, Taiwan). On day 28, the mice were divided randomly into four groups (6 mice/group) to be treated with Tan-IIA (30 mg/kg of body weight, dissolved in corn oil, Q.week days 3 and 5), 5-FU (30 mg/kg of body weight, dissolved in normal saline, Q.week day 1) or Tan-IIA (30 mg/kg of body weight, Q.week days 3 and 5) plus 5-FU (30 mg/kg of body weight, Q.week day 1). As a control, xenografted tumors were separately treated with normal saline (0.1 ml/10 g body weight, Q.week day 1) and corn oil (0.1 ml/10 g body weight, Q.week days 3 and 5). Each agent was injected intraperitoneally. At the end of the 4-week dosing schedule, the SCID mice were sacrificed by CO 2 inhalation on day 35. Following xenograft transplantation, mice exhibiting tumors were monitored, and tumor size was measured once every 2 days using calipers. The tumor volume for each animal was estimated according to the following formula: Tumor volume (mm
(where L is the tumor length and W is the width) with the final measurement taken 5 weeks after tumor cell inoculation. At the same time, the body weight of each animal was measured once every 2 days. The xenograft tumors were dissected and weighed individually before the proteins were extracted for Western blotting. The protein expression of Bax, caspase-3 and CD31 was measured by Western blotting. Immunoreactive bands were scanned and analyzed using a digital scanning densitometer (Molecular Dynamics, Sunnyvale, CA, USA). The experimental design is shown in Fig. 1 .
Statistical analysis. Each value represents the mean ± SD.
The control and experimental animal groups were compared using the Student's t-test. P<0.05 was considered to denote statistical significance.
Results and discussion
The results indicated that Tan-IIA and 5-FU significantly reduced hep-J5 cell xenograft tumor size. Representative animals treated with Tan-IIA relative to the control are shown in Fig. 2 . Tan-IIA treatment significantly decreased tumor volume (Fig. 3A-C) and weight (Fig. 3D) compared with the control. The percent inhibition of tumor weight is shown in Table I . None of the treatments altered the body weight significantly (data not shown). Tumors were only observed at the inoculation sites. Based on these in vivo experiments, it can be seen that Tan-IIA at 30 mg/kg can inhibit tumor growth in a J5 xenograft model. In the present study, tumors in mice that received Tan-IIA alone were approximately 55% smaller than those of the control group (Fig. 3A) . In the 5-FU treatment and Tan-IIA plus 5-FU groups, tumors continued to grow slowly compared with the control group, indicating that complete regression of J5 cell xenografts was not achieved using a single treatment agent, and therefore that multiple treatments may be required to achieve a complete response. However, our results revealed that Tan-IIA possesses therapeutic potential in HCC J5 cells in vivo. This is in agreement with other studies (18) . However, the combination of Tan-IIA and 5-FU was not capable of producing any synergistic effects in J5 cells in vivo (Fig. 3C and D) . Our results also revealed that the protein expression of Bax (Fig. 4A ) and caspase 3 ( Fig. 4B ) in xenograft tumors treated with Tan-IIA and/ or 5-FU was upregulated when compared to the control group. This is in agreement with our previous in vitro study and others (13, 17) . The protein expression of CD31 ( 
